

National Core Curriculum: Stimulants and their Impact on Brain and Behavior – Best Practices and Approaches for Effective Treatment and Recovery

Reference List

- Abadi, M. (2016). This graphic shows just how widespread meth is in the United States. *Business Insider*. Retrieved March 8, 2017, from <https://www.businessinsider.com/>.
- Altarum Institute. (2016). *Sexual Health and Your Patients: A Provider's Guide*. Washington, DC: Author. Available at: <https://nationalcoalitionforsexualhealth.org/tools/for-healthcare-providers/document/ProviderGuide.pdf>.
- American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. (2011, reaffirmed 2017). *Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age*. *Obstetrics and Gynecology*, 117(3), 751–755.
- American Dental Association. (2017). *Oral Health Topics: Methamphetamine*. Retrieved October 1, 2019, from <https://www.ada.org/en/member-center/oral-health-topics/methamphetamine>.
- AshaRani, P. V., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: a systematic review. *Drug and Alcohol Dependence*, 212, 108060.
- Ashford, R. D., Brown, A. M., & Curtis, B. (2018). Substance use, recovery, and linguistics: The impact of word choice on explicit and implicit bias. *Drug and Alcohol Dependence*, 189, 131–138.
- Back, S., Dansky, B. S., Coffey, S. F., Saladin, M. E., Sonne, S., & Brady, K. T. (2010). Cocaine dependence with and without posttraumatic stress disorder: A comparison of substance use, trauma history and psychiatric comorbidity. *American Journal on Addictions*, 9(1), 51–62.
- Barnhorst, A. (2017, September 12). *Amphetamine-Related Psychiatric Disorders Clinical Presentation*. Retrieved June 11, 2020, from <http://emedicine.medscape.com/article/289973-clinical>.
- Bassareo, V., & Di Chiara, G. (1999). Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments. *Neuroscience*, 89(3), 637–641.
- Berg, M. K., Hobkirk, A. L., Joska, J. A., & Meade, C. S. (2017). The role of substance use coping in the relation between childhood sexual abuse and depression among methamphetamine users in South Africa. *Psychological Trauma: Theory, Research, Practice, and Policy*, 9(4), 493–499.
- Berkman, A., Pilowsky, D. J., Zybert, P. A., Herman, D. B., Conover, S., Lemelle, S., Susser, E. (2007). HIV prevention with severely mental ill men: A randomised controlled trial. *AIDS Care*, 19, 579–588.

Best, D., & Laudet, A. (2019). *Opioid 101 Panel: Effective Interventions in Prevention, Treatment and Recovery*. Opioid Response Network.

Betancourt, L. M., Yang, W., Brodsky, N. L., Gallagher, P. R., Malmud, E. K., Giannetta, J. M., ... Hurt, H. (2011). Adolescents with and without gestational cocaine exposure: Longitudinal analysis of inhibitory control, memory and receptive language. *Neurotoxicol Teratol*, 22(1), 33–46.

Blackstone, K., Iudicello, J. E., Morgan, E. E., Weber, E., Moore, D.J., Franklin, ... the TMARC Group. (2013). HIV infection heightens concurrent risk of functional dependence in persons with chronic methamphetamine use. *Journal of Addiction Medicine*, 7(4), 255–263.

Blair, J. M., McNaghten, A. D., Frazier, E. L., Skarbinski, J., Huang, P., & Heffelfinger, J. D. (2011). Clinical and behavioral characteristics of adults receiving medical care for HIV infection: Medical Monitoring Project, United States, 2007. *Morbidity and Mortality Weekly Report*, 60(11), 1–20.

Bramness, J. G., Gundersen, O. H., Gusterstam, J., Rognli, E. B., Konstenius, M., Loberg, E.- M., ... Franck, J. (2012). Amphetamine-induced psychosis – A separate diagnostic entity or primary psychosis triggered in the vulnerable? *BMC Psychiatry*, 12(221), 1–7.

Brecht, M. L., O'Brien, A., von Mayrhauser, C., & Anglin M. D. (2004). *Methamphetamine use behaviors and gender differences*. *Addictive Behavior*. 29(1), 89–106.

Buck, J. M., & Siegel, J. A. (2015). The effects of adolescent methamphetamine exposure. *Frontiers in Neuroscience*, 9(151), 1–5.

Budney, A. J., & Higgins, S. T. (1998). *Therapy Manuals for Drug Addiction: A Community Reinforcement Plus Vouchers Approach: Treating Cocaine Addiction*. NIH Publication Number 98-4309. Washington, DC: National Institute on Drug Abuse.

Cain, M. A., Bornick, P., & Whiteman, V. (2013). The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy. *Clinical Obstetrics and Gynecology*, 56(1), 124–132.

Callaghan, R. C., Cunningham, J. K., Sykes, J., & Kish, S. J. (2011). Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. *Drug and Alcohol Dependence*, 120, 35–40.

Carroll, K., M. (1998). *Therapy Manuals for Drug Addiction: A Cognitive-Behavioral Approach: Treating Cocaine Addiction*. NIH Publication Number 98-4308. Washington, DC: National Institute on Drug Abuse. Available at: <https://archives.drugabuse.gov/sites/default/files/cbt.pdf>.

Carroll, K. M., & Rawson, R. A. (2005). Relapse Prevention for Stimulant Dependence. In G. A. Marlatt & D. M. Donovan (Eds.), *Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, Second Edition*. (pp. 130-150). New York, NY: The Guilford Press.

Carroll, K. M., Rounsaville, B. J., Nich, C., Gordon, L. T., Wirtz, P. W., & Gawin, F. (1994). One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. *Archives of General Psychiatry*, *51*(12), 989–997.

Centers for Disease Control and Prevention. (2020, June 4). *PrEP*. Retrieved June 17, 2020, from <https://www.cdc.gov/hiv/basics/prep.html>.

Center for Substance Abuse Treatment. (1999). *Treatment for Stimulant Use Disorders. Treatment Improvement Protocol (TIP) Series, No. 33*. Rockville, Maryland: Substance Abuse and Mental Health Services Administration Retrieved July 7, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK64323/table/A59093/>.

Center for Substance Abuse Treatment. (2006). *Counselor's Treatment Manual: Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders. HHS Publication No. (SMA) 13-4152*. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019). Pharmacotherapy for methamphetamine/ amphetamine use disorder—A systematic review and meta-analysis. *Addiction*, *114*, 2122–2136.

Chan, B., Kondo, K., Ayers, C., Freeman, M., Montgomery, J., Paynter, R., & Kansagara, D. (2018). *Pharmacotherapy for Stimulant Use Disorders: A Systematic Review*. Washington, DC: U.S. Department of Veterans Affairs.

Cherner, M. (2013, January). The HIV+ brain on drugs: Focus on methamphetamine. *Psychology and AIDS Exchange Newsletter*. Washington, DC: American Psychological Association.

Cherner, M., Suarez, P., Casey, C., Deiss, R., Letendre, S., Marcotte, T., ... HNRC Group (2010). Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. *Drug and Alcohol Dependence*, *106*(2-3), 154–163.

Choi, S. K. Y., Boyle, E., Cairney, J., Gardner, S., Collins, E. J., Bacon, J., ... OHTN Cohort Study Group. (2016). Adequacy of mental health services for HIV-positive patients with depression: Ontario HIV Treatment Network Cohort Study. *PLoS One*, *11*(6), e0156652.

Chiang, M., Lombardi, D., Du, J., Makrum, U., Sitthichai, R., Harrington, A., ... Fan, X. (2019). Methamphetamine-associated psychosis: Clinical presentation, biological basis, and treatment options. *Human Psychopharmacology*, e2710. doi: 10.1002/hup.2710. Epub 2019 Aug 22.

Ciccarone, D. (2011). Stimulant abuse: Pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacology. *Primary Care*, *28*(1), 41–58.

Cohen, J. B., Dickow, A., Horner, K., Zweben, J. E., Balabis, J., Vandersloot, D., ... Methamphetamine Treatment Project (2003). Abuse and violence history of men and women in treatment for methamphetamine dependence. *The American Journal on Addictions*, *12*(5), 377–385.

- Colorado Department of Public Health and Environment, Hazardous Materials and Waste Management Division. (2007). *Cleanup of Clandestine Methamphetamine Labs Guidance Document*. Denver, CO: Colorado Department of Public Health and Environment.
- Copeland, A. L., & Sorensen, J. L. (2001). Differences between methamphetamine users and cocaine users in treatment. *Drug and Alcohol Dependence*, 62(1), 91–95.
- Cornish, J. W., & O'Brien, C. P. (1996). Crack cocaine abuse: An epidemic with many public health consequences. *Annual Review of Public Health*, 17, 259-273.
- Cunningham, C. O., Sohler, N. L., Berg, K. M., Shapiro, S., & Heller, D. (2006). Type of substance use and access to HIV-related health care. *AIDS Patient Care and STDs*, 20, 399–407.
- Curtin, K., Fleckenstein, A. E., Robison, R. J., Crookston, M. J., Smith, K. R., & Hanson, G. R. (2015). Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment. *Drug and Alcohol Dependence*, 146, 30–38.
- Davis, D. R., Kurti, A. N., Skelly, J. M., Redner, R., White, T. J., & Higgins, S. T. (2016). A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014. *Preventive Medicine*, 92, 36–46.
- De Crescenzo, F., Ciabattini, M., D'Alò, G. L., De Giorgi, R., Del Giovane, C., Cassar, C., ... Cipriani, A. (2018). Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. *PLoS Medicine*, 15(12), e1002715.
- Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci U.S.A.*, 85(14), 5274–5278.
- Dolezal, B. A., Chudzynski, J., Dickerson, D., Mooney, L., Rawson, R. A., Garfinkel, A., & Cooper, C. B. (2014). Exercise training improves heart rate variability after methamphetamine dependency. *Medicine and Science in Sports and Exercise*, 46(6), 1057–1066.
- Donovan, D. M. (1999). Assessment Strategies and Measures in Addictive Behaviors. In B. S. McCrady and E. E. Epstein (Eds.), *A Comprehensive Guidebook* (pp. 187-215). New York, NY: Oxford University Press.
- DynamiCare Health. (2020, June 18). *Our Program*. Retrieved on June 18, 2020, from <https://www.dynamicarehealth.com/info>.
- Ellis, M. Kasper, A., Cicero, T. (2018). Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. *Drug and Alcohol Dependence*, 193, 14–20.

- Eze, N., Smith, L. M., LaGasse, L. L., Derauf, C., Newman, E., Arria, A., ... Lester, B. M. (2016). School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the infant development, environment, and lifestyle study. *The Journal of Pediatrics*, *170*, 34–38.
- Faces & Voices of Recovery. (2012, September 17). *Glenn Williams – Young People in Recovery*. [Film]. Retrieved May 29, 2020, from <https://www.youtube.com/watch?v=iYT3Mh0ITzg>.
- Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., ... McKetin, R. (2019). Responding to global stimulant use: challenges and opportunities. *Lancet (London, England)*, *394*(10209), 1652–1667.
- Fernández-Rouco, N., Carcedo, R., Lopez, F., & Begona Orgaz, M. (2019). Mental health and proximal stressors in transgender men and women. *Journal of Clinical Medicine*, *8*(3), 413.
- Fiorino, D. F., & Phillips, A. G. (1997). Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. *Journal of Neuroscience*, *17*(12), 4849–4855.
- Fitzpatrick, R. E., Rubenis, A. J., Lubman, D. I., & Verdejo-Garcia, A. (2020). Cognitive deficits in methamphetamine addiction: Independent contributions of dependence and intelligence. *Drug and Alcohol Dependence*, *209*, (1 April), 107891.
- Foulds, J. A., Boden, J. M., McKetin, R., & Newton-Howes, G. (2020). Methamphetamine use and violence: Findings from a longitudinal birth cohort. *Drug and Alcohol Dependence*, *207*, 107826.
- Garthe, R. C., Hildago, M. A., Hereth, J., Garafalo, R., Reisner, S. L., Mimiaga, M. J., & Kuhns, L. (2018). Prevalence and risk correlates of intimate partner violence among a multisite cohort of young transgender women. *LGBT Health*, *5*(6), 333–340.
- Glasner-Edwards, S., & Mooney, L. J. (2014). Methamphetamine psychosis: Epidemiology and management. *CNS Drugs*, *28*(12), 1115–1126.
- Glick, S. N., Burt, R., Kummer, K., Tinsley, J., Banta-Green, C. J., & Golden, M. R. (2018). Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. *Drug and Alcohol Dependence*, *182*, 86–92.
- Gold, M.S., & Miller, N. S. (1997). Cocaine (and crack): Neurobiology. In: Lowinson, J. H., Ruiz, P., Millman, R. B., & Langrod, J. G., Eds. *Substance Abuse: A Comprehensive Textbook, 3rd Edition*. Baltimore, MD: Williams & Wilkins.
- Grassi, L., Pavanati, M., Cardelli, R., & Ferri, S. (1999). HIV-risk behaviour and knowledge about HIV/AIDS among patients with schizophrenia. *Psychological Medicine*, *29*(1), 171–179.
- Haidich A. B. (2010). Meta-analysis in medical research. *Hippokratia*, *14*(Suppl 1), 29–37.

Hart, C. L., Marvin, C. B., Silver, R., & Smith, E. E. (2012). Is cognitive functioning impaired in methamphetamine users? A critical review. *Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology*, *37*(3), 586–608.

Herbst, J. H., Jacobs, E. D., Finlayson, T. J., McKleroy, V., S., Spink Neumann, M., Crepaz, N., & HIV/AIDS Prevention Research Synthesis Team. (2008). Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. *AIDS Behavior*, *12*, 1–17.

Higgins, S. T., Budney, A. J., Bickel, W. K., Foerg, F. E., Donham, R., & Badger, G. J. (1994). Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. *Archives of General Psychiatry*, *51*(7), 568–576.

Higgins, S. T., & Petry, N. M. (1999). Contingency management. Incentives for sobriety. *Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism*, *23*(2), 122–127.

Higgins, S. T., Sigmon, S. C., Wong, C. J., Heil, S. H., Badger, G. J., Donham, R., ... Anthony, S. (2003). Community reinforcement therapy for cocaine-dependent outpatients. *Archives of General Psychiatry*, *60*(10), 1043–1052.

Hoenigl, M., Chaillon, A., Moore, D. J., Morris, S. R., Smith, D. M., & Little, S. J. (2016). Clear links between starting methamphetamine and increasing sexual risk behavior: A cohort study among men who have sex with men. *Journal of Acquired Immunodeficiency Syndrome*, *71*(5), 551–557.

Kampman, K. M. (2019). The treatment of cocaine use disorder. *Science Advances*, *5*, eaax1532.

Kelly, J. F., & Westerhoff, C. M. (2010). *Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy*, *21*(3), 202–207.

Kim, S. G., Lowe, E. L., Dixit, D., Youn, C. S., Kim, I. J., Jung, J. B., ... Vatakis, D. N. (2015). Cocaine-mediated impact on HIV infection in humanized BLT mice. *Scientific Reports*, *5*(10010), 1–11.

Kmeic, J., (2018). *Substance Induced Disorders* [PowerPoint slides]. Retrieved June 15, 2020, from <https://www.aoaam.org/resources/Documents/2018%20Convention%20Slides/Monday%20-%2010-8-2018%20-%20130pm%20-%20Co-occurring%20Disorders-%20Substance%20Induced%20vs%20Primary%20Psychiatric%20Disorder%20-%20Kmeic1.pdf>.

Knapp, W. P., Soares, B., Farrell, M., & Silva de Lima, M. (2007). Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. *Cochrane Database of Systematic Reviews*, Issue 3. Art. No.: CD003023.

Lappin, J. M., Darke, S., & Farrell, M. (2018). Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. *Drug and Alcohol Dependence*, *187*, 134–140.

Leschner, A. (1997). Addiction is a brain disease, and it matters. *Science*, 278(5335), 45–47.

Lexico. (2020). *Neurotransmitter*. Retrieved January 23, 2020, from <https://www.lexico.com/en/definition/neurotransmitter>.

Ling W., Mooney, L., & Rawson, R. A. (2013). Amphetamine-type stimulants. In B. S. McCrady & E. E. Epstein (Eds.), *Addictions: A comprehensive guidebook, second edition* (pp. 174-190). New York, NY: Oxford University Press.

Liv's Recovery Kitchen. (2018). *Language Matters: A Recovery Scientist Explains the Impact of Our Words*. Retrieved May 29, 2020, from <https://www.livsrecoverykitchen.com/articles/2018/7/10/language-matters-a-recovery-scientist-explains-the-impact-of-our-words>.

Luchansky, B., Krupski, A., & Stark, K. (2007). Treatment response by primary drug of abuse: does methamphetamine make a difference? *Journal of Substance Abuse Treatment*, 32(1), 89–96.

Marinelli-Casey, P. Gonzales, R., Hillhouse, M., Ang, A., Zweben, J., Cohen, J., ... Methamphetamine Treatment Project Corporate Authors. (2008). Drug court treatment for methamphetamine dependence: Treatment response and posttreatment outcomes. *Journal of Substance Abuse Treatment*, 34, 242–248.

Matua Raki National Addiction Workforce Development. (2010). *Consumer and Peer Roles in the Addiction Sector*. Wellington, New Zealand: Author.

Maxwell, J. C. (2019, October 3). DEA Methamphetamine Profiling Program: National Data 2006-2018. [Slide]. In: *Heroin, Meth, and Poly-Substance Abuse: Where We Are Now*. [PowerPoint Presentation]. Austin, TX: Addiction Research Institute, University of Texas at Austin.

Maxwell, J.C. (2014). A new survey of methamphetamine users in treatment: Who they are, why they like “meth,” and why they need additional services. *Substance Use and Misuse*, 49(6), 639–644.

Maxwell, J. C. (Personal Communication October 3, 2019). Reanalysis of methamphetamine survey data.

Maxwell, J. C. (2019, November 9). Methamphetamine Manufacturing Processes. [Slide]. In: *Methamphetamine and the Effectiveness of Various Solutions: It's a Confusing Picture*. [PowerPoint Presentation]. Austin, TX: Addiction Research Institute, University of Texas at Austin.

Maxwell, J. C. (2019, November 9). Purity vs. Potency. [Slide]. In: *Methamphetamine and the Effectiveness of Various Solutions: It's a Confusing Picture*. [PowerPoint Presentation]. Austin, TX: Addiction Research Institute, University of Texas at Austin.

McCance-Katz, E. F., (2019, August 20). *SAMHSA's 2018 National Survey on Drug Use and Health (NSDUH)*. U.S. Department of Health and Human Services, Substance Abuse Mental Health Services Administration. [Webcast]. Available at: <https://www.samhsa.gov/newsroom/speeches-presentations>.

McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [¹¹C]WIN-35,428. *Journal of Neuroscience*, *18*(20), 8417–8422.

McHugh, R. K., Hearon, B. A., & Otto, M. W. (2010). Cognitive behavioral therapy for substance use disorders. *The Psychiatric Clinics of North America*, *33*(3), 511–525.

McKee, J., & Brahm, N. (2016). Medical mimics: Differential diagnostic considerations for psychiatric symptoms. *Mental Health Clinician*, *6*, 289–296.

McKetin, R., Dawe, S., Burns, R. A., Hides, L., Kavanagh, D. J., Teesson, M., ... Saunders, J. B. (2016). The profile of psychiatric symptoms exacerbated by methamphetamine use. *Drug and Alcohol Dependence*, *161*, 104–109.

McKetin, R., Kothe, A., Baker, A. L., Lee, N. K., Ross, J., & Lubman, D. I. (2018). Predicting abstinence from methamphetamine use after residential rehabilitation: Findings from the Methamphetamine Treatment Evaluation Study. *Drug and Alcohol Review*, *37*(1), 70–78.

McKetin, R., Lubman, D. I., Baker, A. L., Dawe, S., & Ali, R. L. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. *JAMA Psychiatry*, *70*(3), 319–324.

McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. (2006). The prevalence of psychotic symptoms among methamphetamine users. *Addiction*, *101*(10), 1473–1478.

Meacham, M. C., Strathdee, S. A., Rangel, G., Armenta, R. F., Gaines, T. L., & Garfein, R. S. (2016). Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico. *J. Stud. Alcohol Drugs*, *77*, 774–781.

Metsch, L. R., Bell, C., Pereyra, M., Cardenas, G., Sullivan, T., Rodriguez, A., ... del Rio, C. (2009). Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. *American Journal of Public Health*, *99*(6), 1045–1049.

Meyers, E. (Director). (2008). *Meth Inside Out: Healing*. [Film]. Los Angeles, CA: Eyes of the World Media Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, E. (Director). (2008). *Meth Inside Out: How the Brain Responds to Methamphetamine*. [Film]. Los Angeles, CA: Eyes of the World Media Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, E. (Director). (2008). *Meth Inside Out: Methamphetamine and Aggression*. [Film]. Los Angeles, CA: Eyes of the World Media Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, E. (Director). (2008). *Meth Inside Out: Methamphetamine and Anhedonia*. [Film]. Los Angeles, CA: Eyes of the World Media Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, E. (Director). (2008). *Meth Inside Out: Methamphetamine Psychosis*. [Film]. Los Angeles, CA: Eyes of the World Medial Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, E. (Director). (2008). *Meth Inside Out: Normal Dopamine Functioning*. [Film]. Los Angeles, CA: Eyes of the World Media Group. Available at: <https://vimeo.com/uclaisap>.

Meyers, R. J., Roozen, H. G., & Smith, J. E. (2011). The community reinforcement approach: an update of the evidence. *Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism*, 33(4), 380–388.

Mid-America Addiction Technology Transfer Center. (2017). *Language Matters: Using Affirmative Language to Inspire Hope and Advance Recovery*. Kansas City, MO: Collaborative to Advance Health Services, School of Nursing and Health Studies, University of Missouri-Kansas City.

Miech, R. A., Schulenberg, J. E., Johnston, L. D., Bachman, J. G., O'Malley, P. M., & Patrick, M. E. (2019, December 19). *National Adolescent Drug Trends in 2019: Findings Released Monitoring the Future*. Ann Arbor, MI: University of Michigan. Retrieved June 11, 2020, from <http://monitoringthefuture.org/data/19data.html#2019data-drugs>.

Miller, N., Gold, M., & Smith, D. (1997). *Manual of Therapeutics for Addictions*. New York, NY: Wiley.

Miller, W. R., & Rollnick, S. (2012). *Motivational Interviewing: Helping People Change*, 3rd Edition. New York, NY: The Guilford Press.

Mooney, L. J., Cooper, C., London, E.D., Chudzynski, J., Dolezal, B., Dickerson, D., ... Rawson, R. (2014). Exercise for methamphetamine dependence: Rationale, design, and methodology. *Contemporary Clinical Trials*, 37, 139–147.

National Institute on Drug Abuse. (2000). *Gender Differences in Drug Abuse Risks and Treatment*. Retrieved May 1, 2020, from <https://archives.drugabuse.gov/news-events/nida-notes/2000/09/gender-differences-in-drug-abuse-risks-treatment>.

National Institute on Drug Abuse. (2016). *The Reward Circuit: How the Brain Responds to Cocaine*. [Film]. Available at: <https://vimeo.com/uclaisap>.

National Institute on Drug Abuse. (2016, May 6). *Cocaine*. Retrieved May 14, 2020, from <https://www.drugabuse.gov/publications/research-reports/cocaine/what-cocaine>.

National Institute on Drug Abuse. (2017, March 9). *Impacts of Drugs on Neurotransmission*. Retrieved May 15, 2020, from <https://www.drugabuse.gov/news-events/nida-notes/2017/03/impacts-drugs-neurotransmission>.

National Institute on Drug Abuse. (2018, July 13). *Cocaine*. Retrieved May 8, 2020, from <https://www.drugabuse.gov/publications/drugfacts/cocaine>.

National Institute on Drug Abuse. (2018, December 13). *Misuse of Prescription Drugs*. Retrieved May 12, 2020, from <https://www.drugabuse.gov/publications/misuse-prescription-drugs/overview>.

National Institute on Drug Abuse. (2019, February 11). *Teaching Addiction Science*. Retrieved June 9, 2020, from <https://www.drugabuse.gov/publications/teaching-addiction-science/brain-actions-cocaine-opioids-marijuana>.

National Institute on Drug Abuse. (2019, February 11). *Understanding Drug Abuse and Addiction: What Science Says: 3: Brain Regions and Their Functions*. Retrieved January 23, 2020, from <https://www.drugabuse.gov/publications/teaching-packets/understanding-drug-abuse-addiction/section-i/3-brain-regions-their-functions>.

National Institute on Drug Abuse. (2019, May 16). *Methamphetamine*. Retrieved May 12, 2020, from <https://www.drugabuse.gov/publications/drugfacts/methamphetamine>.

National Institute on Drug Abuse. (2019, October 16). *Methamphetamine*. Retrieved June 11, 2020, from <https://www.drugabuse.gov/publications/research-reports/methamphetamine/overview>.

National Institute on Drug Abuse. (2020, March 26). *Commonly Used Drugs Charts*. Retrieved May 12, 2020, from <https://www.drugabuse.gov/drugs-abuse/commonly-used-drugs-charts>.

National Institute on Drug Abuse. (2020, April 8). *How is Methamphetamine Manufactured?* Retrieved July 6, 2020, from <https://www.drugabuse.gov/publications/research-reports/methamphetamine/how-methamphetamine-manufactured>.

National Institute on Drug Abuse. (2020, May 29). *Drug Misuse and Addiction*. Retrieved July 6, 2020, from <https://www.drugabuse.gov/sites/default/files/soa.pdf>.

National Institute on Drug Abuse. (2020, June 1). *Contingency Management Interventions/Motivational Incentives (Alcohol, Stimulants, Opioids, Marijuana, Nicotine)*. Retrieved June 1, 2020, from <https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies/contingency-management-interventions-motivational-incentives>.

National Institute for Health Care Management Foundation. (2020, May). *Beyond Opioids: Rapid Increase in Drug Deaths Involving Stimulants*. Retrieved June 3, 2020,

from <https://www.nihcm.org/categories/beyond-opioids-rapid-increase-in-drug-deaths-involving-stimulants>.

Nishimura, M., Ma, J., Thomas, I. C., Fox, S., Toomu, A., Mojaver, S., ... Maisel, A. (2017). Methamphetamine associated heart failure, a new epidemic. *Circulation*, *136*(Suppl_1), A14066–A14066.

Nun. O. (2020, May). *Interactions between HIV Treatment and Recreational Drugs*. Retrieved June 10, 2020, from <https://www.aidsmap.com/about-hiv/interactions-between-hiv-treatment-and-recreational-drugs>.

Oggins, J. (2009). Engaging minority men at HIV risk in integrated mental health and drug treatment. *Journal of Psychoactive Drugs*, *41*(2), 163–171.

Operario, D., & Nemoto, T. (2010). HIV in transgender communities: Syndemic dynamics and a need for multicomponent interventions. *Journal of Acquired Immunodeficiency Syndromes*, *55*(Suppl. 2), S91–S93.

Payer, D., Albisetegui-DuBois, R., Xu, J., & Monterosso, J., Fong, T., Cohen, M., ... London, E. (2005, January 1). *Deficits in Cortical Activation Associated with Emotion Processing in Methamphetamine Abusers*. [Conference presentation abstract]. Society of Neuroscience 35th Annual Meeting.

Pear Therapeutics. (2020, June 18). *reSET-O/reSET*. Retrieved on June 18, 2020, from <https://www.resetforrecovery.com>.

Polcin, D. L., Bond, J., Korcha, R., Nayak, M. B., Galloway, G. P., & Evans, K. (2014). Randomized trial of intensive motivational interviewing for methamphetamine dependence. *Journal of Addictive Disease*, *33*, 253–265.

Poling, J., Oliveto, A., Petry, N., Sofuoglu, A. M., Gonsai, K., Gonzalez, G., ... Kosten, T. R. (2006). Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. *Archives of General Psychiatry*, *63*, 219–228.

Rawson, R. (2019, November 19). Methamphetamine Availability Reduces 2006. [Slide]. In: *The Re-Emergence of Cocaine and Methamphetamine in the 21st Century*. [PowerPoint Presentation]. Burlington, VT: Vermont Center on Behavior and Health, University of Vermont.

Rawson, R. (2019, November 19). *Types of Stimulant Drugs: Amphetamine Type Stimulants (ATS)*. [Slide]. In: *The Re-Emergence of Cocaine and Methamphetamine in the 21st Century*. [PowerPoint Presentation]. Burlington, VT: Vermont Center on Behavior and Health, University of Vermont.

Rawson, R. A., Chudzynski, J., Mooney, L., Gonzales, R., Ang, A., Dickerson, D., ... Cooper, D. B. (2015). Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. *Drug and Alcohol Dependence*, *156*, 21–28.

- Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. *Journal of Substance Abuse Treatment, 23*(2), 145–150.
- Rawson, R. A., Marinelli-Casey, P., Anglin, M. D., Dickow, A., Frazier, Y., Gallagher, C., ... Methamphetamine Treatment Project Corporate Authors (2004). A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. *Addiction (Abingdon, England), 99*(6), 708–717.
- Reback, C. J., Veniegas, R., & Shoptaw, S. (2014). Getting Off: Development of a model program for gay and bisexual male methamphetamine users. *Journal of Homosexuality, 61*, 540–553.
- Richards, J. R., & Laurin, E. G. (2019, November 14). *Methamphetamine Toxicity*. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Retrieved June 11, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK430895/>.
- Sanchez, K., Greer, T. L., Walker, R., Carmody, T., Rethorst, C. D., & Trivedi, M. H. (2017). Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention. *Journal of Ethnicity in Substance Abuse, 16*(4), 495–510.
- Satel, S. L., Southwick, S. M., & Gawin, F. H. (1991). Clinical features of cocaine-induced paranoia. *American Journal of Psychiatry, 148*, 495–498.
- Semple, S. J., Patterson, T. L., & Grant, I. (2002). Motivations associated with methamphetamine use among HIV+ men who have sex with men. *Journal of Substance Abuse Treatment, 22*, 149–156.
- Shoblock, J. R., Sullivan, E. B., Maisonneuve, I. M., & Glick, S. D. (2003). Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. *Psychopharmacology (Berl), 165*(4), 359–369.
- Shoptaw, S., & Reback, C. J. (2006). Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy. *Journal of Urban Health: Bulletin of the New York Academy of Science, 83*(6), 1151–1157.
- Shoptaw, S., & Reback, C. J. (2007). Methamphetamine use and infectious disease-related behaviors in men who have sex with men: Implications for interventions. *Addiction, 102*(Suppl. 1), 130–135.
- Shoptaw, S., Reback, C. J., Peck, J. A., Larkins, S., Freese, T. E., & Rawson, R. A. (2005). *Getting Off: A Behavioral Intervention for Gay and Bisexual Male Methamphetamine Users*. Los Angeles, CA: Friends Research Institute, Inc. Available at: http://uclacbam.org/wp-content/uploads/2018/04/Getting_Off_Behavioral_Treatment_Manual.pdf.
- Shorter, D., & Kosten, T. R. (2011). Novel pharmacotherapeutic treatments for cocaine addiction. *BMC Medicine, 9*, 119–127.

Skolnick, P. (2015). Emerging targets for stimulant use disorders: Where to invest in an era of constrained resources? *CNS & Neurological Disorders - Drug Targets*, 14, 691.

Simon, S. L., Richardson, K., Dacey, J., Glynn, S., Domier, C. P., Rawson, R.A., & Ling, W. (2002). A comparison of patterns of methamphetamine and cocaine use. *Journal of Addictive Diseases*, 21(1), 35–44.

Smid, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant use in pregnancy – an under-recognized epidemic among pregnant women. *Clinical Obstetrics and Gynecology*, 62(1), 168–184.

Smith, R. C., Blumenthal, H., Badour, C., & Feldner, M. T. (2010). An investigation of relations between crystal methamphetamine use and posttraumatic stress disorder, *Addictive Behaviors* 35, 625–627.

Smith, L. M., LaGasse, L. L., Derauf, C., Grant, P., Shah, R., Arria, A., ... Liu, J. (2006). The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. *Pediatrics*, 118(3), 1149–1156.

Stein, M. D., Herman, D. S., & Anderson, B. J. (2009). A motivational intervention trial to reduce cocaine use. *Journal of Substance Abuse Treatment*, 36(1), 118–125.

Substance Abuse and Mental Health Services Administration, Office of the Surgeon General. (2016). *Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health*. Washington, DC: U.S. Department of Health and Human Services.

Substance Abuse and Mental Health Services Administration. (2019). *Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health* (HHS Publication No. PEP 19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2019). *Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment*. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Substance Abuse Mental Health Services Administration. (2020). *Evidence-based Resource Guide Series: Treatment of Stimulant Use Disorders*. Publication No. PEP20-06-01-001. Rockville, MD: SAMHSA. Available at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-06-01-001.pdf.

Svingen, L., Dykstra, R. E., Simpson, J. L., Jaffe, A. E., Bevins, R. A., Carlo, G., ... Grant, K. M. (2016). Associations between family history of substance use, childhood trauma, and age of

first drug use in persons with methamphetamine dependence. *Journal of Addiction Medicine*, 10(4), 269–273.

Tennessee Works. *The Dignity of Risk*. Retrieved May 29, 2020, from <http://www.tennesseeworks.org/the-dignity-of-risk/>.

Tian, X., Ru, Q., Xiong, Q., Yue, K., Chen, L., Ma, B., ... Li, C. (2017). Neurotoxicity induced by methamphetamine-heroin combination in PC12 cells. *Neuroscience Letters*, 647, 1–7.

Tolou-Shams, M., Feldstein Ewing, S. W., Tarantino, N., & Brown, L. K. (2010). Crack and cocaine use among adolescents in psychiatric treatment: Associations with HIV risk. *Journal of Child and Adolescent Substance Abuse*, 19(2), 122–134.

Toussi, S. S., Joseph, A., Zheng, J. H., Dutta, M., Santambrogio, L., & Goldstein, H. (2009). Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. *AIDS Research and Human Retroviruses*, 25(17), 1117–1121.

Trujillo, K. A., Smith, M. L., & Guaderrama, M. M. (2011). Powerful behavioral interactions between methamphetamine and morphine. *Pharmacology, Biochemistry, and Behavior*, 99, 451–458.

United Nations Office of Drugs and Crime. (2019). *Treatment of Stimulant Use Disorders: Current Practices and Promising Perspectives*. Vienna, Austria: UNODC. Available at: [https://www.unodc.org/documents/drug-prevention-and-treatment/Treatment of PSUD for website 24.05.19.pdf](https://www.unodc.org/documents/drug-prevention-and-treatment/Treatment_of_PSUD_for_website_24.05.19.pdf).

United Nations Office of Drugs and Crime. (2020). *World Drug Report 2020*. Vienna, Austria: United Nations.

U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2012). *SAMHSA's Working Definition of Recovery: 10 Guiding Principles of Recovery*. Accessed May 29, 2020, from <https://store.samhsa.gov/sites/default/files/d7/priv/pep12-recdef.pdf>.

U.S. Drug Enforcement Administration (2017). *2017 National Drug Threat Assessment*. Washington, DC: Author. Retrieved June 2, 2020, from https://www.dea.gov/sites/default/files/2018-07/DIR-040-17_2017-NDTA.pdf.

U.S. Drug Enforcement Administration. (2017). Methamphetamine Lab Incidents, 2004-2017, reported by El Paso Intelligence Center (EPIC). Retrieved June 2, 2020, from <https://www.dea.gov/clan-lab>.

U.S. Drug Enforcement Administration. (2019). *2019 National Drug Threat Assessment*, DEA-DCT-DIR-007-20. Washington, D.C.: Author. Available at: https://www.dea.gov/sites/default/files/2020-01/2019-NDTA-final-01-14-2020_Low_Web-DIR-007-20_2019.pdf.

U.S. Drug Enforcement Administration, Diversion Control Division. (2019). *NFLIS-Drug Special Report: Methamphetamine Reported in NFLIS, 2001–2017*. Springfield, VA: U.S. Drug Enforcement Administration.

U.S. Drug Enforcement Administration, Diversion Control Division. (2020). *National Forensic Laboratory Information System: NFLIS-Drug 2019 Midyear Report*. Springfield, VA: U.S. Drug Enforcement Administration.

U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2012). *SAMHSA's Working Definition of Recovery: 10 Guiding Principles of Recovery*. Accessed May 29, 2020, from <https://store.samhsa.gov/sites/default/files/d7/priv/pep12-recdef.pdf>.

Volkow, N. (2005, April 21). Testimony before the Subcommittee on Labor, Health, and Human Services; Education; and Related Agencies. Committee on Appropriations, U.S. Senate.

Volkow, N. D., Chang, L., Wang, G. J., Fowler, J.S., Leonido-Yee, M., Franceschi, D., ... Miller, E. N. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. *American Journal of Psychiatry*, *158*, 377–382.

Volkow, N. D., Fowler, J. S., Wang, G.-J., Hitzemann, R., Logan, J., Schlyer, D., ... Wolf, A. P. (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. *Synapse*, *14*, 169–177.

Volkow, N. D., Hitzemann, R., Wang, G.-J., Fowler, J. S., Wolf, A. P., & Dewey, S. L. (1992). Long-term frontal brain metabolic changes in cocaine abusers. *Synapse* *11*, 184–190.

Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Teland, F. (2011). Addiction: Beyond dopamine reward circuitry. *Proc Natl Acad Sci USA*, *108*(37), 15037–15042.

Walsh, C. (2017). *Revising the Language of Addiction*. The Harvard Gazette. Retrieved May 29, 2020, from <https://news.harvard.edu/gazette/story/2017/08/revising-the-language-of-addiction/>.

Weaver, M. R., Conover, C. J., Proescholdbell, R. J., Arno, P. S., Ang, A., Ettner, S. L., & Cost Subcommittee of the HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study Group. (2008). Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. *Journal of Acquired Immunodeficiency Syndrome*, *47*(4), 449–458.

Werb, D., Kerr, T., Buxton, J., Shoveller, J., Richardson, C., Montaner, J., & Wood, E. (2013). Crystal methamphetamine and initiation of injection drug use among street-involved youth in a Canadian setting. *Canadian Medical Association Journal*, *185*(18), 1569–1575.

Yeon, P. A., & Albrecht, H. (2007, December 3). Crystal meth and HIV/AIDS: The perfect storm? *NEJM Journal Watch*. Retrieved June 1, 2020,

from <https://www.jwatch.org/ac200712030000001/2007/12/03/crystal-meth-and-hiv-aids-perfect-storm>.